Rabbit PARK9 Polyclonal Antibody | anti-ATP13A2 antibody

PARK9 (Probable Cation-transporting ATPase 13A2, ATP13A2)

Cat. Num. AAA645930

• Gene Names: ATP13A2; CLN12; KRPPD; PARK9; HSA9947; RP1-37C10.4
• Reactivity: Human, Monkey, Mouse, Rat
• Applications: Western Blot, Immunoprecipitation
• Purity: Affinity Purified; Purified by Protein A affinity chromatography.
• Synonyms: PARK9; Polyclonal Antibody; PARK9 (Probable Cation-transporting ATPase 13A2; ATP13A2); Anti -PARK9 (Probable Cation-transporting ATPase 13A2; anti-ATP13A2 antibody

• Host: Rabbit
• Reactivity: Human, Monkey, Mouse, Rat
• Clonality: Polyclonal
• Isotype: IgG
• Specificity: Recognizes endogenous levels of total human PARK9. Species Crossreactivity: Monkey, mouse and rat.
• Purity/Purification: Affinity Purified; Purified by Protein A affinity chromatography.
• Form/Format: Supplied as a liquid in 10mM sodium HEPES, pH 7.5, 150mM sodium chloride, 100ug/ml BSA, 50% glycerol.

• Applicable Applications for anti-ATP13A2 antibody: Western Blot (WB), Immunoprecipitation (IP)
• Application Notes: Suitable for use in Western Blot and Immunoprecipitation.; Dilution: Western Blot: 1:1000; Immunoprecipitation: 1:50
• Immunogen: Synthetic peptide corresponding to residues surrounding Ser282 of human PARK9.
• Preparation and Storage: May be stored at 4 degree C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20 degree C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Western Blot (WB)

(Western blot analysis of extracts from HeLa and COS-7 cells using MBS645930.)

Related Product Information for anti-ATP13A2 antibody

Parkinson's disease (PD), the second most common neurodegenerative disease after Alzheimer's, is a progressive movement disorder characterized by rigidity, tremors and postural instability. The pathological hallmark of PD is progressive loss of dopaminergic neurons in the substantia nigra of the ventral midbrain and the pres- ence of intracellular Lewy bodies (protein aggregates of a-synuclein, ubiquitin and other components) in surviving neurons of the brain stem (1). Various genes and loci (a-synuclein/PARK1 and 4, parkin/PARK2, UCH-L1/PARK5, PINK1/PARK6, DJ-1/PARK7, LRRK2/PARK8, ATP13A2/ PARK9) are genetically linked to PD (2). PARK9, also known as ATP13A2, is a member of the P-type ATPase superfamily and is involved in the lysosomal degradation pathway, clearing a-synuclein aggregates (3,4). The protein has 10 transmembrane domains and wild-type PARK9 localizes to the lysosomal membrane. In contrast, all three known mutations, which have premature stop codons resulting in a truncated protein, are retained in the endo- plasmic reticulum and degraded by the proteasome. PARK9 is predominantly expressed in the brain and has been linked to Kufor-Rakeb Syndrome, a monogenic form of recessively inherited, atypical parkinsonism that is characterized by juvenile onset, with pyramidal degeneration and cognitive dysfunction (5,6).

Product Categories/Family for anti-ATP13A2 antibody

Antibodies; Abs to Enzymes; ATPase

NCBI and Uniprot Product Information

• NCBI GI #: 213972621
• NCBI GeneID: 23400
• NCBI Accession #: NP_001135446.1
• NCBI GenBank Nucleotide #: NM_001141974.1
• UniProt Accession #: Q9NQ11; O75700; Q5JXY1; Q5JXY2; Q6S9Z9
• Molecular Weight: 128,794 Da
• NCBI Official Full Name: probable cation-transporting ATPase 13A2 isoform 3
• NCBI Official Synonym Full Names: ATPase type 13A2
• NCBI Official Symbol: ATP13A2
• NCBI Official Synonym Symbols: CLN12; KRPPD; PARK9; HSA9947; RP1-37C10.4
• NCBI Protein Information: probable cation-transporting ATPase 13A2; putative ATPase
• UniProt Protein Name: Probable cation-transporting ATPase 13A2
• Protein Family: Probable cation-transporting ATPase
• UniProt Gene Name: ATP13A2
• UniProt Synonym Gene Names: PARK9
• UniProt Entry Name: AT132_HUMAN

NCBI Description

This gene encodes a member of the P5 subfamily of ATPases which transports inorganic cations as well as other substrates. Mutations in this gene are associated with Kufor-Rakeb syndrome (KRS), also referred to as Parkinson disease 9. Multiple transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Nov 2008]

Uniprot Description

Function: May play a role in intracellular cation homeostasis and the maintenance of neuronal integrity. Ref.12

Catalytic activity: ATP + H2O = ADP + phosphate.

Subcellular location: Membrane; Multi-pass membrane protein

By similarity. Lysosome Ref.11 Ref.12.

Tissue specificity: Expressed in brain; protein levels are markedly increased in brain from subjects with Parkinson disease and subjects with dementia with Lewy bodies. Detected in pyramidal neurons located throughout the cingulate cortex (at protein level). In the substantia nigra, it is found in neuromelanin-positive dopaminergic neurons (at protein level). Ref.12

Involvement in disease: Kufor-Rakeb syndrome (KRS) [MIM:606693]: A rare form of autosomal recessive juvenile or early-onset, levodopa-responsive parkinsonism. In addition to typical parkinsonian signs, clinical manifestations of Kufor-Rakeb syndrome include behavioral problems, facial tremor, pyramidal tract dysfunction, supranuclear gaze palsy, and dementia.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.9 Ref.10 Ref.11 Ref.13 Ref.14 Ref.17

Sequence similarities: Belongs to the cation transport ATPase (P-type) (TC 3.A.3) family. Type V subfamily. [View classification]

Sequence caution: The sequence CAA08912.1 differs from that shown. Reason: Frameshift at position 1054.